Real‐Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The <scp>ARON</scp>‐2 Retrospective Experience
Authors
Maria Teresa Bourlon (ORCID: https://orcid.org/0000-0002-3116-912X)
Real‐Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON‐2 Retrospective Experience
Maria Teresa Bourlon, Halima Abahssain, Zin Myint, Sebastiano Buti et al.
Citations
5 citations
Journal
Cancer Medicine
Topics
Bladder and Urothelial Cancer Treatments
Field-Weighted Citation Impact (FWCI)
10.03
article
Real‐Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON‐2 Retrospective Experience
Maria Teresa Bourlon, Halima Abahssain, Zin Myint, Sebastiano Buti, Camillo Porta, Matteo Santoni, Andrey Soares, Johannes Landmesser, Giandomenico Roviello, Enrique Grande, Javier Molina‐Cerrillo, Mimma Rizzo, Franco Morelli, Lorena Incorvaia, Annalisa Zeppellini, Samer Salah, Francesco Massari, Yüksel Ürün, Alexandr Poprach, Fernando Sabino Marques Monteiro, Lazar Popović, Hideki Takeshita, Shilpa Gupta, Patrizia Giannatempo, Se Hoon Park
article en
5 citations
Abstract
No abstract available for this paper.
Publication Tag
Cancer MedicineVol. 14(4)
Institutions
University of Parma (IT), Cleveland Clinic (US), University of Kentucky (US), Ankara University (TR), University of Novi Sad (RS), Masaryk University (CZ), Casa Sollievo della Sofferenza (IT), Hospital Israelita Albert Einstein (BR), Samsung Medical Center (KR), Markey Cancer Center (US), King Fahad Specialist Hospital (SA), Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT), Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari (IT), Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (MX), Oncology Institute of Vojvodina (RS), University Hospital Schleswig-Holstein (DE), Masaryk Memorial Cancer Institute (CZ), Azienda USL di Bologna (IT), Hospital Sírio-Libanês (BR), Institut National d'Oncologie (MA), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Fondazione IRCCS Istituto Nazionale dei Tumori (IT), Social Insurance Saitama Chuo Hospital (JP), MD Anderson Cancer Center Madrid (ES), Hospital Universitario Ramón y Cajal (ES), Ospedale di Macerata, University of Florence (IT), University of Macerata (IT), University of Bari Aldo Moro (IT), Sungkyunkwan University (KR), Saitama Medical University (JP), Universidad Panamericana (MX), University of Palermo (IT), University of Lübeck (DE), University of Bologna (IT)